PMID- 24991383
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140703
LR  - 20211021
IS  - 1942-2962 (Print)
IS  - 1942-2970 (Electronic)
IS  - 1942-2962 (Linking)
VI  - 6
IP  - 9
DP  - 2013 Nov
TI  - Modeling the Frequency and Costs Associated with Postsurgical Gastrointestinal 
      Adverse Events for Tapentadol IR versus Oxycodone IR.
PG  - 567-75
AB  - BACKGROUND: Few studies have estimated the economic effect of using an opioid 
      that is associated with lower rates of gastrointestinal (GI) adverse events (AEs) 
      than another opioid for postsurgical pain. OBJECTIVE: To estimate the number of 
      postsurgical GI events and incremental hospital costs, including potential 
      savings, associated with lower GI AE rates, for tapentadol immediate release (IR) 
      versus oxycodone IR, using a literature-based calculator. METHODS: An electronic 
      spreadsheet-based cost calculator was developed to estimate the total number of 
      GI AEs (ie, nausea, vomiting, or constipation) and incremental costs to a 
      hospital when using tapentadol IR 100 mg versus oxycodone IR 15 mg, in a 
      hypothetical cohort of 1500 hospitalized patients requiring short-acting opioids 
      for postsurgical pain. Data inputs were chosen from recently published, 
      well-designed studies, including GI AE rates from a previously published phase 3 
      clinical trial of postsurgical patients who received these 2 opioids; GI 
      event-related incremental length of stay from a large US hospital database; drug 
      costs using wholesale acquisition costs in 2011 US dollars; and average 
      hospitalization cost from the 2009 Healthcare Cost and Utilization Project 
      database. The base case assumed that 5% (chosen as a conservative estimate) of 
      patients admitted to the hospital would shift from oxycodone IR to tapentadol IR. 
      RESULTS: In this hypothetical cohort of 1500 hospitalized patients, replacing 5% 
      of oxycodone IR 15-mg use with tapentadol IR 100-mg use predicted reductions in 
      the total number of GI events from 1095 to 1085, and in the total cost of GI AEs 
      from $2,978,400 to $2,949,840. This cost reduction translates to a net savings of 
      $22,922 after factoring in drug cost. For individual GI events, the net savings 
      were $26,491 for nausea; $12,212 for vomiting; and $7187 for constipation. 
      CONCLUSION: Using tapentadol IR in place of a traditional mu-opioid shows the 
      potential for reduced GI events and subsequent cost-savings in the postsurgical 
      hospital setting. In the absence of sufficient real-world data, this 
      literature-based cost calculator may assist hospital Pharmacy & Therapeutics 
      committees in their evaluation of the costs of opioid-related GI events.
FAU - Paris, Andrew
AU  - Paris A
AD  - Independent Research Consultant, Vigilytics LLC, Victor, NY.
FAU - Kozma, Chris M
AU  - Kozma CM
AD  - Independent Research Consultant, Ck Consulting Associates, LLC, St Helena Island, 
      SC.
FAU - Chow, Wing
AU  - Chow W
AD  - Associate Director, Health Economics and Outcomes Research, Janssen Scientific 
      Affairs, LLC.
FAU - Patel, Anisha M
AU  - Patel AM
AD  - Formerly a contractor with Health Economics and Outcomes Research, Janssen 
      Scientific Affairs, LLC.
FAU - Mody, Samir H
AU  - Mody SH
AD  - Director, Translational Science Team, Health Economics and Outcomes Research, 
      Janssen Scientific Affairs, LLC, Raritan, NJ.
FAU - Kim, Myoung S
AU  - Kim MS
AD  - Executive Director, Epidemiology, Medical Affairs, Johnson & Johnson, New 
      Brunswick, NJ.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Health Drug Benefits
JT  - American health & drug benefits
JID - 101479877
PMC - PMC4031735
EDAT- 2014/07/06 06:00
MHDA- 2014/07/06 06:01
PMCR- 2013/11/01
CRDT- 2014/07/04 06:00
PHST- 2014/07/04 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2014/07/06 06:01 [medline]
PHST- 2013/11/01 00:00 [pmc-release]
PST - ppublish
SO  - Am Health Drug Benefits. 2013 Nov;6(9):567-75.